Hassman Research Institute

Recent papers from Hassman Research Institute

1. NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trialsNeuropsychopharmacology · 2026
2. Efficacy, Tolerability, and Safety of TRPC4/5 Inhibitor BI 1358894 in Patients With Major Depressive Disorder and Inadequate Response to AntidepressantsThe Journal of Clinical Psychiatry · 2025
3. Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.2025
4. Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant DepressionThe Journal of Clinical Psychiatry · 2025
5. A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIVClinical Pharmacology in Drug Development · 2025
6. Assessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative studySchizophrenia · 2025
7. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trialsSHILAP Revista de lepidopterología · 2024
8. Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trialJournal of Psychopharmacology · 2024
9. Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA · 2023
10. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studiesJournal of Substance Use and Addiction Treatment · 2023
11. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injectionThe American Journal of Drug and Alcohol Abuse · 2022
12. Healthcare Provider Engagement with a Novel Dashboard for Tracking Medication Ingestion: Impact on Treatment Decisions and Clinical Assessments for Adults with SchizophreniaNeuropsychiatric Disease and Treatment · 2022
13. Phase 3b Multicenter, Prospective, Open-label Trial to Evaluate the Effects of a Digital Medicine System on Inpatient Psychiatric Hospitalization Rates for Adults With SchizophreniaThe Journal of Clinical Psychiatry · 2022
14. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence StudyDrug Design Development and Therapy · 2021
15. Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disordersNeuropsychopharmacology · 2020
16. Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving DupilumabClinical Pharmacology & Therapeutics · 2018